An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

J. Larkin; M.P. Brown; A.M. Arance; A. Hauschild; P. Queirolo; M.D. Vecchio; P.A. Ascierto; I. Krajsová; J. Schachter; B. Neyns; C. Garbe; V.C. Sileni; M. Mandalà; H. Gogas; E. Espinosa; G. Hospers; P. Lorigan; M. Nyakas; A. Guminski; G. Liszkay; P. Rutkowski; W. Miller; M. Donica; M. Makrutzki; C. Blank

doi:10.1016/j.ejca.2018.11.018

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

J. Larkin, M.P. Brown, A.M. Arance, A. Hauschild, P. Queirolo, M.D. Vecchio, P.A. Ascierto, I. Krajsová, J. Schachter, B. Neyns, C. Garbe, V.C. Sileni, M. Mandalà, H. Gogas, E. Espinosa, G. Hospers, P. Lorigan, M. Nyakas, A. Guminski, G. LiszkayP. Rutkowski, W. Miller, M. Donica, M. Makrutzki, C. Blank

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	175-185
Number of pages	11
Journal	European Journal of Cancer
Volume	107
DOIs	https://doi.org/10.1016/j.ejca.2018.11.018
Publication status	Published - 2019

Access to Document

10.1016/j.ejca.2018.11.018

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058680214&doi=10.1016%2fj.ejca.2018.11.018&partnerID=40&md5=cb15c5d9ad2d28db1bc4780eb00f988e

Cite this

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., ... Blank, C. (2019). An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. European Journal of Cancer, 107, 175-185. https://doi.org/10.1016/j.ejca.2018.11.018

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. / Larkin, J.; Brown, M.P.; Arance, A.M.; Hauschild, A.; Queirolo, P.; Vecchio, M.D.; Ascierto, P.A.; Krajsová, I.; Schachter, J.; Neyns, B.; Garbe, C.; Sileni, V.C.; Mandalà, M.; Gogas, H.; Espinosa, E.; Hospers, G.; Lorigan, P.; Nyakas, M.; Guminski, A.; Liszkay, G.; Rutkowski, P.; Miller, W.; Donica, M.; Makrutzki, M.; Blank, C.

In: European Journal of Cancer, Vol. 107, 2019, p. 175-185.

Research output: Contribution to journal › Article › peer-review

Larkin, J, Brown, MP, Arance, AM, Hauschild, A, Queirolo, P, Vecchio, MD, Ascierto, PA, Krajsová, I, Schachter, J, Neyns, B, Garbe, C, Sileni, VC, Mandalà, M, Gogas, H, Espinosa, E, Hospers, G, Lorigan, P, Nyakas, M, Guminski, A, Liszkay, G, Rutkowski, P, Miller, W, Donica, M, Makrutzki, M & Blank, C 2019, 'An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system', European Journal of Cancer, vol. 107, pp. 175-185. https://doi.org/10.1016/j.ejca.2018.11.018

Larkin, J. ; Brown, M.P. ; Arance, A.M. ; Hauschild, A. ; Queirolo, P. ; Vecchio, M.D. ; Ascierto, P.A. ; Krajsová, I. ; Schachter, J. ; Neyns, B. ; Garbe, C. ; Sileni, V.C. ; Mandalà, M. ; Gogas, H. ; Espinosa, E. ; Hospers, G. ; Lorigan, P. ; Nyakas, M. ; Guminski, A. ; Liszkay, G. ; Rutkowski, P. ; Miller, W. ; Donica, M. ; Makrutzki, M. ; Blank, C. / An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. In: European Journal of Cancer. 2019 ; Vol. 107. pp. 175-185.

@article{724d0872432849babe96ca0fbeca600f,

title = "An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system",

author = "J. Larkin and M.P. Brown and A.M. Arance and A. Hauschild and P. Queirolo and M.D. Vecchio and P.A. Ascierto and I. Krajsov{\'a} and J. Schachter and B. Neyns and C. Garbe and V.C. Sileni and M. Mandal{\`a} and H. Gogas and E. Espinosa and G. Hospers and P. Lorigan and M. Nyakas and A. Guminski and G. Liszkay and P. Rutkowski and W. Miller and M. Donica and M. Makrutzki and C. Blank",

note = "Cited By :2 Export Date: 11 February 2020",

year = "2019",

doi = "10.1016/j.ejca.2018.11.018",

language = "English",

volume = "107",

pages = "175--185",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

AU - Larkin, J.

AU - Brown, M.P.

AU - Arance, A.M.

AU - Hauschild, A.

AU - Queirolo, P.

AU - Vecchio, M.D.

AU - Ascierto, P.A.

AU - Krajsová, I.

AU - Schachter, J.

AU - Neyns, B.

AU - Garbe, C.

AU - Sileni, V.C.

AU - Mandalà, M.

AU - Gogas, H.

AU - Espinosa, E.

AU - Hospers, G.

AU - Lorigan, P.

AU - Nyakas, M.

AU - Guminski, A.

AU - Liszkay, G.

AU - Rutkowski, P.

AU - Miller, W.

AU - Donica, M.

AU - Makrutzki, M.

AU - Blank, C.

N1 - Cited By :2 Export Date: 11 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1016/j.ejca.2018.11.018

DO - 10.1016/j.ejca.2018.11.018

M3 - Article

VL - 107

SP - 175

EP - 185

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -